What Preventis does

Preventis GmbH is a German point-of-care diagnostics company founded in 2003 and headquartered in Bensheim, Germany (Darmstadt registration HRB 25632), led by Managing Director Dr. Franz Paul Armbruster. The company develops qualitative, semi-quantitative, and quantitative lateral-flow rapid tests organized around four clinical specialties: gastroenterology, infectious diseases, reproductive medicine, and oncology. Its flagship QuantOn® technology converts standard lateral-flow cassettes into smartphone-quantified assays: a product-specific companion app scans the test cassette and derives a quantitative measurement by analyzing the color intensity of the test bands, producing results the company states are comparable with parameter-specific laboratory gold standards. Product lines include the SmarTest® app-based self-tests (Vitamin D Home, Calprotectin Home, FIT Home), the PreventID® professional and home-use lateral-flow assays (CC, Chlamydia, RSV, Entamoeba histolytica, SARS-CoV-2 antibody, H. pylori antigen, Vital-D, Ovulation, Haemo/HaptOccult, Lyme Borreliosis), and the underlying QuantOn® platform. SmarTest Calprotectin became Preventis's first product to receive IVDR Class C self-test certification from BSI in July 2025, representing the highest-risk self-test class under EU IVDR.

Preventis operates a hybrid go-to-market combining direct-to-consumer e-commerce via shop.preventis.com (consumer self-testing), B2B field sales of PreventID® professional tests to medical practices, pharmacies, and laboratories, and a corporate occupational-health services arm that delivers colorectal-cancer, bladder-cancer, and vitamin-D screening programs to German employers. Distribution is international via four localized storefronts (German, English, French, Dutch), and the company maintains partnerships with awareness organizations such as the Network Against Colorectal Cancer and the Felix Burda Foundation, plus an IT vendor and lab-services partner (Immundiagnostik AG for ELISA dry-blood analysis on Vital-D). In November 2025 Preventis announced a strategic partnership with Camlog to extend its POC diagnostics into dental settings, signaling an intent to broaden beyond the existing four-specialty footprint. Pricing is not publicly disclosed; consumer products are sold via e-commerce checkout while occupational-health corporate programs are quoted on a per-engagement basis. The customer mix is intrinsically diversified across anonymous individual self-testers, healthcare-professional buyers, and corporate occupational-health clients, with no disclosed enterprise-anchor concentration.

Name

Preventis

Legal name

Preventis GmbH

Website

https://preventis.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Preventis GmbH is a Bensheim, Germany-based point-of-care diagnostics company developing qualitative and quantitative lateral-flow rapid tests across gastroenterology, infectious diseases, reproductive medicine, and oncology, serving consumers via SmarTest app-based self-tests, healthcare professionals with PreventID assays, and corporate clients with occupational-health screening programs.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)

akta.pro secondary industries

Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Point-of-care diagnostics
• Lateral flow rapid tests
• Colorectal cancer screening
• Self-testing diagnostics
• Quantitative immunoassays

Headquarters

HQ city

Istanbul

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Point-of-Care Diagnostic Products: Sale of lateral flow rapid tests (qualitative, semi-quantitative, and quantitative) for self-testing and professional use. Products include SmarTest branded app-based tests and PreventID branded professional tests.
2. Corporate Occupational Health Services: B2B occupational health services for corporate customers including colorectal cancer, bladder cancer, and Vitamin D prevention programs tailored to company size and workforce composition.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Preventis GmbH manufactures and distributes point-of-care lateral flow rapid diagnostic tests, offering qualitative, semi-quantitative, and quantitative test kits across gastroenterology, infectious diseases, reproductive medicine, and oncology. The portfolio includes two distinct product lines: SmarTest app-based self-tests using proprietary QuantOn technology for smartphone-quantified results, and PreventID professional and home-use rapid tests. Products serve three use cases: direct-to-consumer self-testing via the company's e-commerce shop, B2B supply to healthcare professionals, and corporate occupational health screening programs.

Product overview

Preventis offers a comprehensive portfolio of point-of-care lateral flow rapid diagnostics, combining classical rapid tests with app-based SmarTest solutions powered by the proprietary QuantOn technology. The product range spans gastroenterology (colon cancer screening, IBD monitoring with calprotectin), infectious diseases (Chlamydia, RSV, H. pylori, Lyme, SARS-CoV-2), women's health (ovulation testing), cardiovascular health, metabolism (vitamin D), and intolerances. The core offerings include: Preventis SmarTest series (Vitamin D Home, Calprotectin Home, FIT Home) which feature smartphone app-based quantitative evaluation; PreventID product line (CC, Chlamydia, RSV, Entamoeba histolytica, SARS-CoV-2-Antikörper, H. pylori Antigen, Vital-D, Ovulation, Haemo/HaptOccult, Lyme Borreliosis) for professional and home use; and the QuantOn technology platform enabling quantitative results from lateral flow tests via image analysis. Tests range from qualitative to semi-quantitative to fully quantitative, with results available within minutes.

Differentiator

Problem solved

Functional benefit

Brands

• Preventis SmarTest: App-based rapid diagnostic tests with smartphone evaluation using QuantOn technology
• PreventID
• QuantOn

Products and services

• Preventis SmarTest Vitamin D Home App-based lateral flow rapid test combined with a Preventis smartphone app for quantitative determination of vitamin D levels at home. Measures vitamin D in 15 minutes by scanning the test cassette via the smartphone app; results are comparable to gold-standard laboratory methods. Targeted at consumers performing self-testing and at-home health monitoring.
• Preventis SmarTest Calprotectin Home App-based fecal calprotectin rapid test for therapy monitoring of inflammatory bowel diseases (IBD). Enables remote patient monitoring by quantifying calprotectin levels via smartphone app, reducing clinic visits. Targeted at IBD patients and gastroenterology practices.
• Preventis SmarTest FIT Home App-based immunologic rapid test for detecting human blood in stool as a colorectal cancer screening tool. Uses gold-conjugated anti-hemoglobin antibodies with smartphone app evaluation via QuantOn. Provides results in 15 minutes. Sensitivity at cutoff 9.6 μg/g: 31.5%, Specificity: 93%, Detection limit: 2.1 μg/g. Targeted at consumers seeking home-based colorectal cancer screening.
• PreventID CC (Home) Immunological occult blood rapid test for home use in colorectal cancer screening. Qualitatively detects human hemoglobin in stool as a marker for intestinal bleeding. Targeted at consumers and professionals performing at-home colorectal cancer screening.
• PreventID Chlamydia Rapid immunochromatographic test for the qualitative detection of Chlamydia antigen. Provides results within 10 minutes. Targeted at healthcare professionals and clinics for point-of-care infectious disease screening.
• PreventID RSV Rapid immunochromatographic test for the qualitative detection of respiratory syncytial virus (RSV) antigens in nasopharyngeal swabs or nasal aspirates. Targeted at healthcare professionals for point-of-care respiratory infection screening.
• PreventID Entamoeba histolytica Rapid chromatographic immunological test for the qualitative detection of Entamoeba histolytica antigens in human stool. Targeted at healthcare professionals for gastrointestinal infection screening.
• PreventID SARS-CoV-2-Antikörper Quantitative rapid test for detecting anti-SARS-CoV-2 IgG antibodies in whole blood, serum, or plasma after SARS-CoV-2 infection or vaccination. Targeted at healthcare professionals and clinics.
• PreventID H. pylori Antigen Immunochromatographic rapid test for the qualitative detection of H. pylori antigens in stool samples to support diagnosis of H. pylori infection. Targeted at healthcare professionals for gastroenterology diagnostics.
• PreventID Vital-D Dry blood spot test for determining 25(OH)-vitamin D status. Uses capillary blood collection with laboratory analysis via ELISA diagnostics from Immundiagnostik AG. Concentration range of 2.3 to 150 ng/ml. Targeted at healthcare professionals and laboratories.
• PreventID Ovulation (test strip) Rapid test for the detection of luteinizing hormone (LH) in urine to identify fertile days in the monthly cycle. Targeted at consumers and women's health practices.
• PreventID Haemo/HaptOccult Immunochromatographic occult blood test for self-tests that detects both hemoglobin and hemoglobin-haptoglobin complexes in stool. Provides enhanced colorectal cancer screening with broader detection spectrum. Sensitivity 89.7% and specificity 99.2% for combined hemoglobin/haptoglobin detection. Targeted at consumers and professional screening programs.
• PreventID Lyme Borreliosis Rapid test for detecting Borrelia-specific IgM and IgG antibodies in whole blood, serum, or plasma. Results can be read after 10 minutes. Targeted at healthcare professionals for infectious disease screening.
• Corporate Occupational Health Programs Tailored B2B corporate health prevention programs covering colorectal cancer screening, bladder cancer screening, and Vitamin D prevention. Programs are customized to company size and workforce composition. Currently available only in Germany. Targeted at corporate HR and occupational health buyers.

Quantifiable outcome

• SmarTest FIT Home detects colorectal cancer risk almost as reliably as lab tests (DKFZ study)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• CamlogcoreStrategic or Co-development Partner · 17 November 2025Preventis and Camlog announced a partnership for dental Point-of-Care diagnostics, extending Preventis diagnostics into dental healthcare settings.
• Network Against Colorectal Cancer (Netzwerk gegen Darmkrebs)coreStrategic or Co-development PartnerJoint efforts to make colorectal cancer screening more accessible and motivate thousands of people to participate in early detection annually. Partnership involves educational outreach and screening program support.
• Liftric GmbHminorImplementation/ SI/ Consulting PartnerService provider for delegated tasks in data processing, based at MAFINEX-Technologiezentrum, Julius-Hatry-Straße 1, 68163 Mannheim

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• QuidelOrtho: US-listed specialist in rapid lateral flow diagnostics (Sofia, QuickVue, Triage product lines) covering infectious disease, women's health and cardiac markers. Directly comparable to Preventis for professional-use and OTC rapid tests, although at significantly greater scale.
• CTK Biotech: Developer and manufacturer of lateral flow rapid tests for infectious disease, fertility and oncology, with both professional and consumer self-test offerings. Comparable to Preventis across product format (lateral flow), use-case breadth and channel strategy.
• Hangzhou AllTest Biotech: Chinese lateral flow rapid test manufacturer with broad infectious disease, fertility and drug-of-abuse product lines sold through international distributors. Closely comparable on platform technology and product breadth, though typically at lower price points than Preventis.
• SD Biosensor: South Korea-headquartered manufacturer of lateral flow rapid diagnostic tests across infectious disease, fertility and other specialties with global distribution. Closely comparable to Preventis on platform (lateral flow), product breadth, and target customer mix between consumer self-tests and professional POC.
• Acon Labs: Manufacturer of lateral flow rapid diagnostic tests (pregnancy/fertility, infectious disease, drugs of abuse, cardiac) sold OTC and to professionals globally. Similar product mix to Preventis's PreventID catalogue and similar multi-region, multi-channel GTM approach.

Emerging players

• GenBody: Asia-based lateral flow diagnostics developer focused on infectious disease, respiratory and women's health POC tests, scaling globally. Comparable product-platform overlap with Preventis, particularly on rapid infectious disease and fertility tests.
• Bühlmann Laboratories: Swiss specialty diagnostics company known for fecal calprotectin testing (Bühlmann Calprotectin / IBD testing). Direct overlap with Preventis's SmarTest Calprotectin Home franchise in IBD self-monitoring and a useful comparable on the EU regulatory pathway for fecal calprotectin POC tests.

Broad incumbents

• Roche Diagnostics: Largest global IVD player with extensive rapid test, POC and digital diagnostics offerings across cobas, Accu-Chek and related platforms. Competes indirectly with Preventis in gastroenterology, vitamin D and infectious disease testing through hospital and pharmacy channels.
• bioMérieux: Global in vitro diagnostics company with a substantial POC and rapid-test franchise (e.g. VITEK, BioFire, VIDAS) overlapping with Preventis on infectious disease and clinical rapid testing. A larger incumbent against which Preventis must differentiate via QuantOn smartphone quantification.
• Abbott Diagnostics: Global IVD and rapid diagnostics incumbent whose BinaxNOW, Panbio and i-STAT lines occupy OTC and professional POC channels overlapping with Preventis's gastroenterology, infectious disease and women's health tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCetBVDipoIRdZkkMq6rl7kQ
• Facebookfacebook.com/preventisdiagnostik
• Instagraminstagram.com/preventis_global
• Xx.com/preventis_

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Preventis